Semaglutide

Semaglutide is a medication used to treat type 2 diabetes. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. Semaglutide works by stimulating insulin secretion and reducing glucagon production in response to meals, leading to lower blood sugar levels. It is available in different formulations, including once-weekly injections and daily oral tablets, and is often used in combination with other diabetes medications to help control blood sugar levels and promote weight loss in patients with type 2 diabetes.

 FAQs

  • Semaglutide is a GLP-1 receptor agonist originally developed to help manage type 2 diabetes. It is now also FDA-approved for chronic weight management in adults with obesity or overweight conditions, especially when paired with diet and exercise.

  • Semaglutide mimics the hormone GLP-1 (glucagon-like peptide-1), which helps regulate blood sugar, slow gastric emptying, and reduce appetite. This leads to lower calorie intake and supports both blood glucose control and weight loss.

  • Semaglutide is available in two primary forms:

    • Injection (once weekly): Most common for both diabetes and weight loss

    • Oral tablet (once daily): Available for diabetes management only

  • For weight loss or type 2 diabetes, semaglutide is typically injected once a week, on the same day each week. Your provider will guide you through a dosing schedule that gradually increases to reduce side effects.

  • Common side effects include:

    • Nausea or vomiting

    • Constipation or diarrhea

    • Headache

    • Fatigue

    • Decreased appetite

    Most side effects lessen as your body adjusts. Serious but rare risks include pancreatitis, gallbladder disease, and thyroid tumors. Always discuss risks with your provider.

  • Not necessarily. Semaglutide may not be appropriate for individuals with a history of pancreatitis, certain endocrine disorders, or family history of medullary thyroid cancer. Your healthcare provider will evaluate your medical history to determine if it's the right fit.

  • Some people notice decreased appetite and modest weight loss within the first few weeks. More significant results typically develop over 8 to 12 weeks, depending on your dose, lifestyle, and metabolism.

  • Yes, semaglutide is often combined with other antidiabetic agents such as metformin or SGLT2 inhibitors. However, your provider will tailor your medication plan to avoid low blood sugar or drug interactions.

  • Yes, clinical trials and real-world data support the long-term safety and effectiveness of semaglutide for both weight management and glycemic control, especially when monitored by a healthcare professional.

Tirzepatide

Tirzepatide is a medication used to treat type 2 diabetes. It belongs to a class of drugs known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. Tirzepatide works by stimulating both GIP and GLP-1 receptors, leading to improved glycemic control and weight management in patients with type 2 diabetes. It is administered as a once-weekly injection and is often used in combination with other diabetes medications to achieve optimal blood sugar control.

 FAQs

  • Tirzepatide is a dual-action injectable medication that mimics GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—two natural hormones involved in blood sugar control and appetite regulation. This dual action helps improve insulin sensitivity, reduce appetite, and support weight loss while maintaining better blood glucose levels.

    • Significant weight loss in individuals with or without diabetes

    • Improved blood sugar control in type 2 diabetes

    • Reduced appetite and food cravings

    • Supports cardiometabolic health

    • Once-weekly dosing for convenience and compliance

  • Tirzepatide is administered as a once-weekly subcutaneous injection, typically on the same day each week. Your provider will start you at a low dose and gradually increase it to improve tolerance and minimize side effects.

  • Tirzepatide may not be appropriate for everyone. Individuals with a history of pancreatitis, medullary thyroid cancer, or certain gastrointestinal conditions may not be candidates. A thorough evaluation by your provider is essential.

  • Common side effects include:

    • Nausea

    • Diarrhea or constipation

    • Decreased appetite

    • Fatigue

    • Indigestion

    These are usually mild and improve over time. More serious but rare side effects include pancreatitis, gallbladder issues, or thyroid tumors. Your provider will monitor you closely throughout treatment.

  • Yes. Clinical trials show significant weight reduction, with many patients losing 15–20% or more of their body weight when combined with a healthy diet and exercise. It’s FDA-approved for type 2 diabetes and under review/available off-label for weight management in non-diabetic patients.

  • Yes. Long-term studies have shown that Tirzepatide is generally safe and effective when used under medical supervision, especially when accompanied by lifestyle changes and regular monitoring.

  • Yes, Tirzepatide can be used alongside other medications like metformin, SGLT2 inhibitors, or insulin, though adjustments may be needed to avoid low blood sugar (hypoglycemia). Your provider will guide your medication regimen.

  • Most patients begin to notice reduced appetite and modest weight loss within a few weeks. Blood sugar improvements and more significant weight changes are typically observed over 8–12 weeks and continue with consistent use.